E
LSL Pharma Group Inc. LSL.V
TSX
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

09/30/2024 06/30/2024 03/31/2024 12/31/2023 09/30/2023
Net Income 24.95% -81.56% 40.62% 38.43% 26.40%
Total Depreciation and Amortization 2.61% 2.10% 37.92% -30.58% 20.27%
Total Amortization of Deferred Charges -- -- -- -- --
Total Other Non-Cash Items -39.11% 66.60% 278.78% -159.82% 9.91%
Change in Net Operating Assets 25.98% 71.00% -415.99% 80.85% -763.89%
Cash from Operations 18.41% 94.48% -99.84% 60.82% -27,105.97%
Capital Expenditure -29.16% -68.55% -164.16% 552.63% 18.98%
Sale of Property, Plant, and Equipment -- -- -- -- --
Cash Acquisitions 98.57% -- -- -- --
Divestitures -- -- -- -- --
Other Investing Activities 17.52% -37.03% 25.36% -680.11% -151.35%
Cash from Investing 56.83% -362.94% -205.86% 406.87% 11.98%
Total Debt Issued 300.68% -65.18% 1,449.26% -97.24% 251.86%
Total Debt Repaid 18.07% -165.45% -147.49% 661.58% 53.39%
Issuance of Common Stock -81.84% 166.25% -- -- --
Repurchase of Common Stock -- -- -- -- --
Issuance of Preferred Stock -- -- -- -- --
Repurchase of Preferred Stock -- -- -- -- --
Total Dividends Paid -- -- -- -- --
Other Financing Activities 54.67% -262.86% 63.06% 2.46% -41.37%
Cash from Financing -62.92% 41.21% 649.33% -83.77% --
Foreign Exchange rate Adjustments -- -- -- -- --
Miscellaneous Cash Flow Adjustments -- -- -- -- --
Net Change in Cash -138.93% 874.01% -213.01% 106.62% -136.22%
Weiss Ratings